PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1778487
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1778487
Tacrolimus Market Growth, Size, Trends Analysis - By Product Type, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Tacrolimus Market Introduction and Overview
According to SPER market research, 'Global Tacrolimus Market Size- By Product Type, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Tacrolimus Market is predicted to reach 12.35 billion by 2034 with a CAGR of 5.86%.
Tacrolimus is used in combination with other medications to avoid rejection (the immune system's attack on a transplanted organ) in people who have had kidney transplants. Tacrolimus is also used in conjunction with other medications to prevent rejection in recipients of liver, lung, or heart transplants. Tacrolimus is an immunosuppressant. It works by inhibiting immune system activity, preventing it from damaging the transplanted organ.
Restraints: Tacrolimus may result in serious adverse effects, including neurotoxicity, diabetes, hyperglycemia, nephrotoxicity, infection, and hypertension. These unfavourable side effects frequently result in treatment termination, which limits tacrolimus market growth. The market growth for tacrolimus is further constrained by the availability of substitute medications.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product Type, By Application, By End-User
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered Abbott Laboratories, Astellas Pharma Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, GSK plc, Lupin Pharmaceuticals Ltd, Novartis, Pfizer Inc, Takeda Pharmaceutical Company Limited.
Global Tacrolimus Market Segmentation:
By Product Type: Based on the Product Type, Global Tacrolimus Market is segmented as; Tablets & Capsules, Injections, Others.
By Application: Based on the Application, Global Tacrolimus Market is segmented as; Immunosuppression, Dermatitis, Others.
By End-User: Based on the End-User, Global Tacrolimus Market is segmented as; Hospitals, Clinics, Others.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Tacrolimus Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tacrolimus Market
7. Global Tacrolimus Market, By Product Type (USD Million) 2021-2034
- 7.1. Tablets & Capsules
- 7.2. Injections
- 7.3. Others
8. Global Tacrolimus Market, By Application (USD Million) 2021-2034
- 8.1. Immunosuppression
- 8.2. Dermatitis
- 8.3. Others
9. Global Tacrolimus Market, By End-User (USD Million) 2021-2034
- 9.1. Hospitals
- 9.2. Clinics
- 9.3. Others
10. Global Tacrolimus Market, (USD Million) 2021-2034
- 10.1. Global Tacrolimus Market Size and Market Share
11. Global Tacrolimus Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Abbott Laboratories
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Astellas Pharma Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Biocon Ltd
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. F. Hoffmann-La Roche Ltd
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Glenmark Pharmaceuticals Ltd
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. GSK plc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Lupin Pharmaceuticals Ltd
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Novartis
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4 .Recent developments
- 12.9. Pfizer Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Takeda Pharmaceutical Company Limited
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
